Symbols

SILO

Silo Pharma·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SILO

Silo Pharma, Inc.

A developmental stage biopharmaceutical company that developing products for indications such as PTSD and Alzheimer's disease

Industry

Pharmaceutical

Established Date

07/13/2010

Listing Date

09/27/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.silopharma.com

Security Type

Common stock

Office address

677 N. Washington Boulevard, Sarasota, FL 34236

Business

Introduction

Silo Pharma, Inc., was incorporated in New York State on July 13, 2010. On January 24, 2013, the Company changed its domicile from New York to Delaware. On December 19, 2023, the company changed its state of incorporation from Delaware to Nevada. The company is a development-stage biopharmaceutical and cryptocurrency company focused on developing novel therapies for unmet needs such as post-traumatic stress disorder, stress anxiety disorder, fibromyalgia and central nervous system diseases. Its main program, SPC-15, is an intranasal drug candidate for the treatment of post-traumatic stress disorder and stress anxiety disorder.

Company Financials

EPS

SILO has released its 2025 Q2 earnings. EPS was reported at -0.19, versus the expected 0, missing expectations. The chart below visualizes how SILO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SILO has released its 2025 Q4 earnings report, with revenue of 18.03K, reflecting a YoY change of 0.00%, and net profit of -881.53K, showing a YoY change of 49.06%. The Sankey diagram below clearly presents SILO's revenue sources and cost distribution.